Terguride: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Created page with "{{Drugbox | verifiedrevid = 437134889 | IUPAC_name = ''N'',''N''-diethyl-''N'''-[(8α)-6-methylergolin-8-yl]urea | image = Terguride.png <!--Clinical data--> | tradename =...")
 
m (Protected "Terguride": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)))
 
(One intermediate revision by one other user not shown)
Line 35: Line 35:
| smiles = CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C
| smiles = CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C
}}
}}
              __NOTOC__
{{SI}}
{{CMG}}
==Overview==


'''Terguride''' ([[International Nonproprietary Name|INN]]) is a [[serotonin]] [[antagonist]]. It is used for the treatment of hyperprolactinemia. Terguride is an oral, potent antagonist of 5-HT2B and 5-HT2A (serotonin) receptors.  Serotonin stimulates the proliferation of pulmonary artery smooth muscle cells, and induces fibrosis in the wall of pulmonary arteries.  Together, this causes vascular remodeling and narrowing of the pulmonary arteries.  These changes result in increased vascular resistance and PAH.  Due to the potential anti-proliferative and anti-fibrotic activity of terguride, this potential medicine could offer the hope of achieving reversal of pulmonary artery vascular remodeling and attenuation of disease progression.<ref>Janssen W, Schymura Y, Novoyatleva T, Kojonazarov B, Boehm M, Wietelmann A, Luitel H, Murmann K, Krompiec DR, Tretyn A, Pullamsetti SS, Weissmann N, Seeger W, Ghofrani HA, Schermuly RT. 5-HT2B Receptor Antagonists Inhibit Fibrosis and Protect from RV Heart Failure. ''Biomed Research International''. 2015;2015:438403. doi 10.1155/2015/438403 PMID 25667920</ref>
'''Terguride''' ([[International Nonproprietary Name|INN]]) is a [[serotonin]] [[antagonist]]. It is used for the treatment of hyperprolactinemia. Terguride is an oral, potent antagonist of 5-HT2B and 5-HT2A (serotonin) receptors.  Serotonin stimulates the proliferation of pulmonary artery smooth muscle cells, and induces fibrosis in the wall of pulmonary arteries.  Together, this causes vascular remodeling and narrowing of the pulmonary arteries.  These changes result in increased vascular resistance and PAH.  Due to the potential anti-proliferative and anti-fibrotic activity of terguride, this potential medicine could offer the hope of achieving reversal of pulmonary artery vascular remodeling and attenuation of disease progression.<ref>Janssen W, Schymura Y, Novoyatleva T, Kojonazarov B, Boehm M, Wietelmann A, Luitel H, Murmann K, Krompiec DR, Tretyn A, Pullamsetti SS, Weissmann N, Seeger W, Ghofrani HA, Schermuly RT. 5-HT2B Receptor Antagonists Inhibit Fibrosis and Protect from RV Heart Failure. ''Biomed Research International''. 2015;2015:438403. doi 10.1155/2015/438403 PMID 25667920</ref>


In May 2008, terguride was granted [[orphan drug]] status for the treatment of [[pulmonary arterial hypertension]].<ref>[http://www.presseportal.ch/de/pm/100015139/100561578/ergonex_pharma_gmbh Presseportal (Swiss press portal, in German)]</ref>
In May 2008, terguride was granted [[orphan drug]] status for the treatment of [[pulmonary arterial hypertension]].<ref>[http://www.presseportal.ch/de/pm/100015139/100561578/ergonex_pharma_gmbh Presseportal (Swiss press portal, in German)]</ref>
In May 2010 [[Pfizer]] purchased world-wide rights for the drug.<ref>[http://www.theday.com/article/20100513/BIZ02/305139376/1044 TheDay.com 5/10/2010]</ref>
In May 2010 Pfizer purchased world-wide rights for the drug.<ref>[http://www.theday.com/article/20100513/BIZ02/305139376/1044 TheDay.com 5/10/2010]</ref>




== References ==
== References ==
{{Reflist}}
{{Reflist|2}}




{{Other gynecologicals}}
{{Dopaminergics}}


[[Category:Dopamine agonists]]
[[Category:Dopamine agonists]]
[[Category:Orphan drugs]]
[[Category:Orphan drugs]]
[[Category:Ureas]]
[[Category:Ureas]]
 
[[Category:Drug]]
 
{{genito-urinary-drug-stub}}

Latest revision as of 17:14, 20 August 2015

Terguride
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
UNII
KEGG
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC20H28N4O
Molar mass340.46 g/mol
3D model (JSmol)
  (verify)

WikiDoc Resources for Terguride

Articles

Most recent articles on Terguride

Most cited articles on Terguride

Review articles on Terguride

Articles on Terguride in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Terguride

Images of Terguride

Photos of Terguride

Podcasts & MP3s on Terguride

Videos on Terguride

Evidence Based Medicine

Cochrane Collaboration on Terguride

Bandolier on Terguride

TRIP on Terguride

Clinical Trials

Ongoing Trials on Terguride at Clinical Trials.gov

Trial results on Terguride

Clinical Trials on Terguride at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Terguride

NICE Guidance on Terguride

NHS PRODIGY Guidance

FDA on Terguride

CDC on Terguride

Books

Books on Terguride

News

Terguride in the news

Be alerted to news on Terguride

News trends on Terguride

Commentary

Blogs on Terguride

Definitions

Definitions of Terguride

Patient Resources / Community

Patient resources on Terguride

Discussion groups on Terguride

Patient Handouts on Terguride

Directions to Hospitals Treating Terguride

Risk calculators and risk factors for Terguride

Healthcare Provider Resources

Symptoms of Terguride

Causes & Risk Factors for Terguride

Diagnostic studies for Terguride

Treatment of Terguride

Continuing Medical Education (CME)

CME Programs on Terguride

International

Terguride en Espanol

Terguride en Francais

Business

Terguride in the Marketplace

Patents on Terguride

Experimental / Informatics

List of terms related to Terguride

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Terguride (INN) is a serotonin antagonist. It is used for the treatment of hyperprolactinemia. Terguride is an oral, potent antagonist of 5-HT2B and 5-HT2A (serotonin) receptors. Serotonin stimulates the proliferation of pulmonary artery smooth muscle cells, and induces fibrosis in the wall of pulmonary arteries. Together, this causes vascular remodeling and narrowing of the pulmonary arteries. These changes result in increased vascular resistance and PAH. Due to the potential anti-proliferative and anti-fibrotic activity of terguride, this potential medicine could offer the hope of achieving reversal of pulmonary artery vascular remodeling and attenuation of disease progression.[1]

In May 2008, terguride was granted orphan drug status for the treatment of pulmonary arterial hypertension.[2] In May 2010 Pfizer purchased world-wide rights for the drug.[3]


References

  1. ↑ Janssen W, Schymura Y, Novoyatleva T, Kojonazarov B, Boehm M, Wietelmann A, Luitel H, Murmann K, Krompiec DR, Tretyn A, Pullamsetti SS, Weissmann N, Seeger W, Ghofrani HA, Schermuly RT. 5-HT2B Receptor Antagonists Inhibit Fibrosis and Protect from RV Heart Failure. Biomed Research International. 2015;2015:438403. doi 10.1155/2015/438403 PMID 25667920
  2. ↑ Presseportal (Swiss press portal, in German)
  3. ↑ TheDay.com 5/10/2010
Retrieved from "https://www.wikidoc.org/index.php?title=Terguride&oldid=1137639"